As our mission at Trackpaw is to drive the development of safe and effective pharmaceuticals by digitalising the preclinical landscape, we're very pleased to have seen the paradigm shift opting for digital preclinical studies truly skyrocketing in 2023.
We're delighted to share our key highlights:
📄 Patent Pending: We filed for our first patent, safeguarding key hardware innovations and their applications.
🤝 Board Expansion: We had the pleasure of welcoming prominent figures in life sciences and distribution experts to our board, fortifying our strategic guidance for 2024's commercial activities.
🚀 Team Expansion: Our team grew with brilliant minds in electronics engineering, mechanical engineering, and system architecture, steering the development of our beta version prototype which will be launched in 2024.
🌐 Successful Pilot Trial: We're happy to share that our first customer-based pilot trial yielded satisfying results in an end-user environment, paving the way for continued projects!
👥 Nurturing our partnerships: With several global site visits with end users in the bag, we've aligned our product development with the real needs of the market.
💼 Successful pre-seed round: Last but not least - Welcoming new owners to our cap table, which not only fuels our 2024 initiatives but also motivates our daily operations.
We are truly gaining speed, and are thankful for the support given by stakeholders, collaborators and future customers. We wish you all joyous celebrations and a fantastic New Year! 🎄
